Moderna Inc. ($MRNA) Stock Forecast: Up 5.3% Today

What is Moderna Inc.?

Moderna (MRNA): Moderna is a leading biotechnology company renowned for its mRNA technology, particularly notable for its advancements in vaccine development during the recent health crisis. The company's stock saw a notable surge in value today.

Why is Moderna Inc. going up?

MRNA stock is up 5.3% on Apr 1, 2026 15:41

• The recent upward trend in Moderna's stock price can be linked to its strategic shift towards oncology research and the development of next-gen respiratory solutions, underscoring a focus on sustained growth opportunities extending beyond the realm of pandemic-related vaccines.
• Investor enthusiasm is likely fueled by Moderna's dedicated efforts in oncology, particularly the promising outcomes in personalized neoantigen therapy for melanoma, signaling positive market responses to the company's diversification.
• Moderna's target of achieving profitability by 2028, backed by a substantial cash reserve and a recent legal settlement, instills further confidence among investors regarding the company's trajectory.
• Noteworthy progress in resolving the ongoing patent dispute with Arbutus Biopharma Corp (ABUS) may have also contributed to the positive momentum of Moderna's stock, as a favorable resolution in legal matters could help alleviate uncertainties for stakeholders.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

ABUS Should I Buy

Arbutus Biopharma Corp (ABUS) is not recommended as a strong buy for beginner, long-term investors due to a lack of clear positive momentum, absence of significant trading signals, and unimpressive financial performance. While the company boasts strong liquidity and a significant Q4 2025 revenue increase, it faces challenges with declining net income and EPS, and an ongoing patent dispute with Moderna. Analysts from Jefferies maintain a Buy rating but acknowledge the complexities of the patent case.

https://intellectia.ai/en/stock/ABUS/should-i-buy

FDA’s Approval Sparks Optimism for Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) saw its stock price surge by over 10% following the FDA's approval of Imcivree's expanded indication for treating acquired hypothalamic obesity. Major financial institutions like Citi and BofA have raised their price targets for Rhythm, citing this approval as a significant growth catalyst and reinforcing the company's leadership in rare obesity treatments. This expanded commercial scope and investor optimism suggest a promising future trajectory for the company despite some financial hurdles.

https://stockstotrade.com/news/rhythm-pharmaceuticals-inc-rytm-news-2026_03_31/

Denali Therapeutics receives $200 million from royalty agreement after FDA approval

Denali Therapeutics Inc. received $200 million in gross proceeds from a synthetic royalty funding agreement with Royalty Pharma, following the FDA's accelerated approval of tividenofusp alfa. This approval, for the treatment of Hunter syndrome, has led several financial firms to raise their price targets for Denali. The drug is the first commercial product from Denali's Transport Vehicle platform.

https://m.investing.com/news/sec-filings/denali-therapeutics-receives-200-million-from-royalty-agreement-after-fda-approval-93CH-4590407?ampMode=1

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

Moderna (NASDAQ: MRNA) is undergoing a significant strategic pivot, transitioning from primarily a COVID-19 vaccine producer to focusing on oncology and next-generation respiratory combinations, a phase CEO Stéphane Bancel refers to as "Moderna 2.0." Despite a decline in COVID-related revenue and a net loss in 2025, the company aims for profitability by 2028, bolstered by a substantial cash reserve and a recent legal settlement. This shift is highlighted by promising data in individualized neoantigen therapy for melanoma and new leadership focused on cancer drug development.

https://markets.financialcontent.com/stocks/article/finterra-2026-3-31-moderna-20-the-mrna-pioneers-pivot-to-oncology-and-the-path-to-2028-profitability

Roivant Sciences Insider Sold Shares Worth $1,921,500, According to a Recent SEC Filing

An insider at Roivant Sciences sold shares valued at $1,921,500, as disclosed in a recent SEC filing. This transaction follows other recent insider sales reported in March, including sales of $5,648,000 and $1,200,573 worth of shares. Roivant Sciences is a biopharmaceutical company focused on developing and commercializing medicines across various therapeutic areas.

https://www.marketscreener.com/news/roivant-sciences-insider-sold-shares-worth-1-921-500-according-to-a-recent-sec-filing-ce7e51ded88af625

Trending Today

Lemonda Inc. ($LMND) Stock Forecast: Down 5.6% Today

Exxon Mobil Corporation ($XOM) Stock Forecast: Down 5.0% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Up 5.7% Today

Intel Corporation ($INTC) Stock Forecast: Up 8.8% Today

Alexandria Real Estate Equities Inc. ($ARE) Stock Forecast: Down 6.9% Today

Hasbro Inc. ($HAS) Stock Forecast: Down 5.1% Today

Alcoa Corporation ($AA) Stock Forecast: Up 8.3% Today

The Boeing Company ($BA) Stock Forecast: Up 5.1% Today

Groupon Inc. ($GRPN) Stock Forecast: Down 5.2% Today

Philip Morris International Inc ($PM) Stock Forecast: Down 5.0% Today

Moderna Inc. Price History

10.02.2026 - MRNA Stock was up 5.8%

• Moderna's stock surged by 6.13% to an intraday high, showcasing robust investor confidence and market demand for the company's products.
• The company's narrower-than-expected Q4 loss and sales beating estimates indicate a positive financial performance, contributing to the bullish movement.
• Strong short-term gains, including an 89.01% year-to-date increase, coupled with high institutional holdings at 80.65%, further bolster investor sentiment in Moderna.
• Eric Green's retirement at West Pharmaceutical, a key player in vaccine distribution, may have indirectly contributed to positive market sentiment towards Moderna, emphasizing the critical role of vaccine-related companies in the current economic landscape.

18.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock declined by 3.77% today.
• Institutional selling pressure, specifically with one entity reducing its stake, has impacted the stock causing short-term uncertainty.
• Despite exceeding earnings expectations and receiving positive feedback on its mRNA flu vaccine from regulatory authorities, the stock is facing a downward trend due to conflicting technical indicators and expert opinions.
• Market sentiment towards Moderna remains cautious as worries about potential risks outweigh recent company achievements and progress in precision medicine.

18.02.2026 - MRNA Stock was down 5.7%

• Moderna Inc. (MRNA) encountered a downward trend in the market today, grappling with obstacles related to its pipeline projects and financial pressures.
• Factors such as decreased demand for its COVID-19 vaccine, Spikevax, and scrutiny surrounding its pipeline advancements have influenced the stock's downturn.
• Investors are reassessing the company's future prospects as Moderna transitions focus towards diverse therapies like mRNA oncology and rare diseases, causing uncertainties in the market.
• Despite holding a substantial cash reserve, notable R&D expenses, and varied efficacy outcomes in certain trials, Moderna's stock performance has been adversely affected by the challenges it is currently facing.

27.02.2026 - MRNA Stock was down 6.0%

• Moderna's stock (MRNA) faced a bearish movement, potentially attributed to profit-taking following a period of strong performance.
• Despite being a key player in the biotech industry and expanding its pipeline, investors may have reacted cautiously to potential challenges in the vaccine market and broader biotech sector.
• The company's shift towards treatments for respiratory viruses, oncology, and rare diseases may not have immediately captured market optimism, contributing to the bearish movement.
• The market's trajectory could also be influenced by general sector trends or broader economic factors impacting investor sentiment towards biotech stocks.

27.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock experienced a significant drop today, possibly influenced by the broader market sentiment affected by the U.S.-Iran conflict and policy deadlines.
• The internal realignment by Vanguard, resulting in 0 reported shares, might have also contributed to the downward pressure on Moderna's stock.
• Despite ongoing growth potential from strategic partnerships and promising pipelines, the stock faced short-term selling pressure, reflecting investor concerns.
• The market's negative reaction to the overall uncertainty and rising oil prices could have led to the decline in Moderna's stock, creating potential buying opportunities for investors eyeing high-quality stocks.

27.02.2026 - MRNA Stock was down 5.2%

• A realignment announcement by Vanguard of 0 MRNA shares might have created uncertainty among investors, leading to a sell-off of Moderna stock.
• The comparison between ImmunityBio and Moderna, highlighting Moderna's broader pipeline and financial stability, could have influenced investors to shift their focus towards ImmunityBio, impacting Moderna's stock price negatively.
• Despite being a leading player in the biotech sector and strategically diversifying its pipeline, Moderna's stock might have faced downward pressure due to concerns about the company's ability to sustain growth beyond its COVID-19 vaccine.
• The potential for significant growth over the next five years for Moderna might not have been enough to offset the immediate bearish sentiment surrounding the stock today.

17.02.2026 - MRNA Stock was up 5.5%

• Today's positive movement in Moderna's stock price is linked to a recent federal court decision blocking proposed changes to the U.S. vaccine policy, a move by Health Secretary Robert F. Kennedy Jr. This ruling has provided stability for Moderna amidst concerns of policy changes impacting biotech revenues.
• Noteworthy insider selling by key individuals such as Moderna President Stephen Hoge, alongside decreased stake holdings by investment entities like Militia Capital Partners LP, contrasts the company's robust financial performance. With $1.9 billion in total revenue for 2025, investor trust in Moderna remains strong.
• The introduction of IQVIA.ai, an advanced AI platform developed in partnership with NVIDIA, to enhance operational efficiency and decision-making in the life sciences domain, may have positively influenced market sentiment towards forward-thinking biotech firms like Moderna.
• Criticism directed at the FDA for inconsistent actions, particularly concerning Moderna's vaccine submissions, underscores regulatory uncertainties that could impact the company's future initiatives and market dynamics. Nonetheless, Moderna's resilience and expansion beyond COVID-related products could help mitigate potential risks.

01.03.2026 - MRNA Stock was up 5.3%

• The recent upward trend in Moderna's stock price can be linked to its strategic shift towards oncology research and the development of next-gen respiratory solutions, underscoring a focus on sustained growth opportunities extending beyond the realm of pandemic-related vaccines.
• Investor enthusiasm is likely fueled by Moderna's dedicated efforts in oncology, particularly the promising outcomes in personalized neoantigen therapy for melanoma, signaling positive market responses to the company's diversification.
• Moderna's target of achieving profitability by 2028, backed by a substantial cash reserve and a recent legal settlement, instills further confidence among investors regarding the company's trajectory.
• Noteworthy progress in resolving the ongoing patent dispute with Arbutus Biopharma Corp (ABUS) may have also contributed to the positive momentum of Moderna's stock, as a favorable resolution in legal matters could help alleviate uncertainties for stakeholders.

31.02.2026 - MRNA Stock was up 5.3%

• The positive investor sentiment towards the company's strategic shift towards oncology and next-generation therapies is likely the driving force behind the recent bullish movement of the company's stock.
• Favorable data on individualized neoantigen therapy for melanoma and the company's emphasis on cancer drug development are factors contributing to the market's positive response to the company's new direction.
• The selling of shares by an insider at a different company may have indirectly impacted the company's stock positively, potentially leading investors to view the company's strategic pivot more favorably.
• The company's proactive approach to diversifying its portfolio and focusing on innovative therapies appears to have resonated well with investors, leading to the upward movement in its stock price.

09.02.2026 - MRNA Stock was down 5.4%

• Sienna Gestion and Quantbot Technologies LP both made significant reductions in their stakes in Moderna, Inc., indicating a lack of confidence in the company's future performance.
• Concerns about Moderna's cash burn post a costly patent settlement and insider selling have led to a cautious outlook among analysts, resulting in a "Reduce" rating and a reduced average price target.
• While the bullish options flow and the resolution of legal issues have generated some positive sentiment, uncertainty regarding regulations and the financial repercussions of the settlement are dampening the stock's performance.
• In summary, today's downward trend in Moderna's stock can be attributed to a mix of decreased investor confidence, financial issues, and regulatory uncertainties stemming from the recent patent settlement.

11.02.2026 - MRNA Stock was up 5.6%

• Reduction of stake in Moderna by 25.3% by Jefferies Financial Group initially sparked concerns regarding the company's future outlook. However, the strong bullish movement today indicates ongoing investor optimism towards Moderna's growth potential.
• Uptick in Moderna's stock following US vaccine advisors' decision not to question mRNA COVID shots could have boosted investor confidence in the company. This move reaffirms faith in mRNA technology, crucial for Moderna's vaccine innovation.
• Moderna's stock surged 6.13% to hit a day high, outperforming the S&P 500. This indicates a positive market response to the company's recent performance and its potential for future growth, despite past long-term declines.
• Favorable sentiment in the therapeutics sector, marked by companies surpassing revenue expectations, may have also contributed to the bullish movement in Moderna's stock. Investors are demonstrating increased interest in the healthcare industry overall.

12.02.2026 - MRNA Stock was down 5.1%

• The decline in Moderna's stock could be linked to profit-taking by institutional investors such as Jefferies Financial Group, which notably decreased its holdings in the company.
• Resolving patent disputes related to its COVID-19 vaccine possibly created uncertainty among investors, despite the settlement and licensing agreements in place.
• Reports of a federal vaccine advisory panel scrapping plans to scrutinize mRNA COVID shots might have raised worries about regulatory challenges or public reception of Moderna's mRNA technology.
• Analysts' consensus "Reduce" rating and apprehensions about inflated valuations likely added to the negative sentiment surrounding Moderna's stock movement.